Royalty Pharma plc RPRX
We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. 10-K, Item 1
- Headquarters
- New York, NY
- CEO
- Pablo G. Legorreta
- Next results
- around Feb 10, 2027
RPRX among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
7 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 11, 2026 against Feb 12, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
9 checks on the latest 10-K. Checks, not verdicts.
1fact worth reading about the other 8 checks found nothing to note
-
Critical audit matters changedNew this year: Initial recognition and valuation of Employee EPAs assumed as part of the Internalization (“As described in Note 3 to the consolidated financial statements, on May 16, 2025, the Company completed its acquisition of Royalty Pharma Manager, LLC for total consideration of $565.2 million (the “Internalization”). The transaction was accounted for as a business combination. As a result of the In”). Same as last year: Valuation of Financial Royalty Assets and related Interest Income
-
Cash from operations $2.5B vs net income $770.9M (FY ending Dec 31, 2025)
7 more checks with nothing to note
-
Same auditor in both 10-Ks: Ernst & Young LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
7 paragraphs in Risk Factors that were not in the 10-K filed Feb 12, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 12, 2025 10-K, ITEM 1A
We may not realize the anticipated benefits of the Internalization or we may be exposed to new risks and costs.
-
Item 1A · new paragraph · not in the 10-K filed Feb 12, 2025 10-K, ITEM 1A
Whether we are a PFIC is a complex legal and factual question. We regularly review whether we expect to be classified as a PFIC in the current year or are likely to be classified as a PFIC in a future year. We may reach the conclusion in future years that we should not be classified as a PFIC.
-
Item 1A · new paragraph · not in the 10-K filed Feb 12, 2025 10-K, ITEM 1A
Beginning in the second quarter of 2025, we did not receive from Vertex the full amount of royalty receipts on Alyftrek net sales to which we believe that we are contractually entitled. Accordingly, we commenced the dispute resolution procedures contemplated by the agreements relating to our royalties on Vertex’s cystic fibrosis…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $2.2B | $2.4B | $2.3B | $2.4B |
| Net income | $42.8M | $1.1B | $859.0M | $770.9M |
| Operating cash flow | $2.1B | $3.0B | $2.8B | $2.5B |
Revenue, FY2018 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$2.4B ▲ 5.1% in FY2025$770.9M ▼ 10.2% in FY2025
Recent filings
5 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 4, 2026Terrance Coyne (Executive Vice President & Chief Financial Officer) adopted a 10b5-1 trading plan reported in the 10-Q, up to 250,000 shares, runs to Feb 24, 2027
-
Planned saleNov 4, 2026Marshall Urist, M.D., Ph.D. (Executive Vice President, Research & Investments) adopted a 10b5-1 trading plan reported in the 10-Q, up to 150,000 shares, runs to Feb 2, 2027
-
Planned saleNov 4, 2026Chris Hite (Executive Vice President & Chairman, Partnering & Investments) adopted a 10b5-1 trading plan reported in the 10-Q, up to 323,200 shares, runs to Mar 12, 2027
-
8-KNov 4, 2026Quarterly results 8-K item 2.02
-
10-QNov 4, 2026Quarterly report (10-Q) period ended Sep 30, 2026
About the company
Royalty Pharma plc, New York, NY · from the 10-K filed Feb 11, 2026
We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies.
- Headquarters
- New York, NY
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 4, 2026
- Incorporated in
- United Kingdom
Email alerts
Sources
The 10-K filed Feb 11, 2026 (open at SEC), compared with the 10-K filed Feb 12, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RPRX/export.csv") into a cell.